Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Inclusion Criteria: * Males or females ≥18 years * Histologically confirmed relapsed/refractory CLL who received ≥1 lines of prior therapy * At least one bi-dimensionally measurable nodal lesion \>1.5 cm * Adequate renal, hepatic function * Adequate hematologic parameters at screening Exclusion Criteria: * Subjects who relapsed or progressed on BCL-2 inhibitor * Relapsed within 2 years of discontinuation of prior PI3K inhibitor (PI3Ki) therapy or disease progression on PI3Ki therapy * History or currently active HBV, HCV; any uncontrolled active infection, HIV infection; HIV-related lymphoma * History of Richter's transformation or prolymphocytic leukemia * Known allergies to both xanthine oxidase inhibitors and rasburicase, or any excipients of the drug products * Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure * Pregnant women